Holen Sie sich die Stockscreener-App
17.17
2.28%
-0.40
Handel nachbörslich:
17.30
0.13
+0.76%
Schlusskurs vom Vortag:
$17.57
Offen:
$17.45
24-Stunden-Volumen:
218.38K
Relative Volume:
0.81
Marktkapitalisierung:
$825.16M
Einnahmen:
$3.96M
Nettoeinkommen (Verlust:
$-141.49M
KGV:
-5.5478
EPS:
-3.0949
Netto-Cashflow:
1W Leistung:
-9.63%
1M Leistung:
-25.74%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.90
$17.50
1-Wochen-Bereich:
$16.36
$19.14
52-Wochen-Spanne:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Firmenname
Odyssey Therapeutics Inc
Sektor
Branche
Telefon
(212) 841-1000
Adresse
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
17.17 | 825.16M | 3.96M | -141.49M | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Odyssey Therapeutics Inc Stock (ODTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | UBS | Buy |
| 2026-10-09 | Eingeleitet | Raymond James | Outperform |
| 2026-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-06-02 | Eingeleitet | JP Morgan | Overweight |
| 2026-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2026-06-02 | Eingeleitet | TD Cowen | Buy |
| 2026-06-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Odyssey Therapeutics Inc Aktie (ODTX) Neueste Nachrichten
City Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance
UBS initiates Odyssey Therapeutics stock with buy rating on IBD drug - Investing.com Canada
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages - MarketBeat
State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX - MarketBeat
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - Yahoo Finance
Electra Therapeutics, Inc. Common stock (ETRA) stock price, news, quote and history - Yahoo Finance Australia
A biotech presentation is set for Sept. 23. Odyssey Therapeutics will take part online. - Stock Titan
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - Kalkine
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Eastern Progress
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - MarketBeat
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.ca
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Vogenx Announces Pricing of Initial Public Offering - Yahoo Finance
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - simplywall.st
ODTX Forecast & Price Target - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - theglobeandmail.com
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics: Q2 Earnings Snapshot - barchart.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Yahoo Finance
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - MarketBeat
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - Yahoo Finance
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Finanzdaten der Odyssey Therapeutics Inc-Aktie (ODTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Odyssey Therapeutics Inc-Aktie (ODTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):